Menostar

Menostar is a brand name of estradiol, approved by the FDA in the following formulation(s):

MENOSTAR (estradiol - film, extended release; transdermal)

• 
  Manufacturer: BAYER HLTHCARE
  
  Approval date: June 8, 2004
  
  Strength(s): 0.014MG/24HR ^[RLD]

Has a generic version of Menostar been approved?

No. There is currently no therapeutically equivalent version of Menostar available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Menostar. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Methods for treating postmenopausal women using ultra-low doses of estrogen
  Patent 5,891,868
  Issued: April 6, 1999
  Inventor(s): Cummings; Steven & Ellman; Herman & Ettinger; Bruce
  Assignee(s): Kaiser Foundation Health Plan, Inc.
  Permanente Medical Group, Inc.
  The Regents of the University of California
  Berlex Laboratories
  The present invention provides methods for treating physical conditions resulting from postmenopausal estrogen decline in a postmenopausal subject, and in particular methods for reducing the risk of osteoporotic bone fractures in a postmenopausal subject. The present invention also provides a kit useful for carrying out the methods of the present invention.
  
  Patent expiration dates:
  
  
  • November 21, 2017
    
    ✓ 
    Patent use: PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
    ✓ 
    Drug product
  
  



• 
  Methods for treating postmenopausal women using ultra-low doses of estrogen
  Patent 6,692,763
  Issued: February 17, 2004
  Inventor(s): Steven R.; Cummings & Bruce; Ettinger & Herman; Ellman
  Assignee(s): The Regents of the University of California
  Kaiser Foundation Health Plan, Inc.
  The Permanente Medical Group, Inc.
  Berlex Laboratories, Inc.
  The present invention provides methods for treating physical conditions resulting from postmenopausel estrogen decline in a postmenopausel subject, and in particular methods for reducing the risk of osteoporotic bone fractures in a postmenopausal subject. The present invention also provides a kit for carrying out the methods of the present invention.
  
  Patent expiration dates:
  
  
  • November 21, 2017
    
    ✓ 
    Patent use: PREVENTION OF POSTMENOPAUSAL OSTEOPOROSIS
    ✓ 
    Drug product
  
  

See also...

• Menostar Consumer Information (Drugs.com)
• Menostar Weekly Patch Consumer Information (Wolters Kluwer)
• Menostar Consumer Information (Cerner Multum)
• Estradiol Consumer Information (Drugs.com)
• Estradiol Consumer Information (Wolters Kluwer)
• Estradiol Acetate Consumer Information (Wolters Kluwer)
• Estradiol Cypionate Consumer Information (Wolters Kluwer)
• Estradiol Gel Consumer Information (Wolters Kluwer)
• Estradiol Gel Packets Consumer Information (Wolters Kluwer)
• Estradiol Patch Consumer Information (Wolters Kluwer)
• Estradiol Ring Consumer Information (Wolters Kluwer)
• Estradiol Spray Consumer Information (Wolters Kluwer)
• Estradiol Valerate Consumer Information (Wolters Kluwer)
• Estradiol Weekly Patch Consumer Information (Wolters Kluwer)
• Estring Ring Consumer Information (Wolters Kluwer)
• Estradiol injection Consumer Information (Cerner Multum)
• Estradiol oral Consumer Information (Cerner Multum)
• Estradiol topical for use on skin Consumer Information (Cerner Multum)
• Estradiol transdermal Consumer Information (Cerner Multum)
• Estradiol vaginal Consumer Information (Cerner Multum)
• Estradiol AHFS DI Monographs (ASHP)